Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology

Milind Javle, Chung-Tsen Hsueh, Milind Javle, Chung-Tsen Hsueh

Abstract

We have reviewed the pivotal presentations rcelated to colorectal cancer (CRC) and other gastrointestinal malignancies from 2008 annual meeting of the American Society of Clinical Oncology (ASCO). We have discussed the scientific findings and the impact on practice guidelines and ongoing clinical trials. The report on KRAS status in patients with metastatic CRC receiving epidermal growth factor receptor (EGFR) targeted antibody treatment has led to a change in National Comprehensive Cancer Network guideline that recommends only patients with wild-type KRAS tumor should receive this treatment. The results of double biologics (bevacizumab and anti-EGFR antibody) plus chemotherapy as first-line treatment in patients with metastatic CRC has shown a worse outcome than bevacizumab-based regimen. Microsatellite Instability has again been confirmed to be an important predictor in patients with stage II colon cancer receiving adjuvant treatment. Adjuvant gemcitabine therapy for pancreatic cancer was investigated by the CONKO-001 study; this resulted in superior survival as compared with observation and can be regarded as an acceptable option, without the addition of radiotherapy. The addition of bevacizumab to gemcitabine and erlotinib was not supior to gemcitabine and erlotinib for advanced disease. Second-line therapy for advanced pancreatic cancer with 5-fluorouracil and oxaliplatin resulted in a survival benefit. Irinotecan plus cisplatin and paclitaxel plus cisplatin result in similar survival when combined with radiotherapy for esophageal cancer. The novel fluoropyrimidine S1 appears to be active in gastric cancer, as a single agent or as combination therapy. Adjuvant intraperitoneal mitomycin-C may decrease the incidence of peritoneal recurrence of gastric cancer. Sorafenib is an effective agent in Asian patients with hepatocellular carcinoma secondary to hepatitis B; its utility in child's B cirrhosis remains to be proven. Sunitinib is also an active agent in hepatocellular carcinoma, and may represent an alterative to sorafenib for advanced disease. These and other important presentations from the 2008 ASCO annual meeting are discussed in this article.

References

    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96. doi: 10.3322/CA.2007.0010.
    1. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005;23:1803–1810. doi: 10.1200/JCO.2005.08.037.
    1. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem. 1990;265:7709–7712.
    1. Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst. 1998;90:675–684. doi: 10.1093/jnci/90.9.675.
    1. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, Andre T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26:374–379. doi: 10.1200/JCO.2007.12.5906.
    1. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626–1634. doi: 10.1200/JCO.2007.14.7116.
    1. Van Cutsem E, Nowacki M, Lang I, Cascinu S, Shchepotin I, Maurel J, Rougier P, Cunningham D, Nippgen J, Kohne C. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol (Meeting Abstracts) 2007;25:4000.
    1. Van Cutsem E, Lang I, D'haens G, Moiseyenko V, Zaluski J, Folprecht G, Tejpar S, Kisker O, Stroh C, Rougier P. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol (Meeting Abstracts) 2008;26:2.
    1. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, Zampino M, Donea S, Ludwig H, Zubel A, Koralewski P. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. J Clin Oncol (Meeting Abstracts) 2007;25:4035.
    1. Bokemeyer C, Bondarenko I, Hartmann JT, De Braud FG, Volovat C, Nippgen J, Stroh C, Celik I, Koralewski P. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol (Meeting Abstracts) 2008;26:4000.
    1. Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, Mirtsching B, Cohn AL, Pippas AW, Azarnia N, Tsuchihashi Z, Mauro DJ, Rowinsky EK. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol. 2006;24:4914–4921. doi: 10.1200/JCO.2006.06.7595.
    1. Tejpar S, Peeters M, Humblet Y, Gelderblom H, Vermorken J, Viret F, Glimelius B, Ciardiello F, Kisker O, Van Cutsem E. Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data. J Clin Oncol (Meeting Abstracts) 2007;25:4037.
    1. Tejpar S, Peeters M, Humblet Y, Vermorken JB, De Hertogh G, De Roock W, Nippgen J, von Heydebreck A, Stroh C, Van Cutsem E. Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data) J Clin Oncol (Meeting Abstracts) 2008;26:4001.
    1. NCCN Practice Guidelines for Colorectal Cancer Version 3. NCCN. 2008;2008
    1. European public assessment report-Vectibix
    1. Action letter – KRAS mutational status and cetuximab therapy in colorectal cancer
    1. Physician fact sheet – N0147
    1. Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, Kemeny NE, Hollywood EM, Gonen M, Quinones M, Morse M, Chen HX. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol. 2007;25:4557–4561. doi: 10.1200/JCO.2007.12.0949.
    1. Hecht J, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, Shahin S, Griffin T. An updated analysis of safety and efficacy of oxaliplatin/bevacizumab ± panitumumab for first-line treatment of metastaticcolorectal cancer from a randomized, controlled trial (PACCE) American Society of Clinical Oncology: Gastrointestinal Cancers Symposium; Orlando, FL. p. 273.
    1. Punt CJ, Tol J, Rodenburg CJ, Cats A, Creemers GM, Schrama JG, Erdkamp FL, Vos A, Mol L, Antonini NF. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG) J Clin Oncol (Meeting Abstracts) 2008;26:LBA4011.
    1. Wiering B, Oyen W, Sijp J Van der, Roumen R, De Jong K, Comans E, Pruim J, Dekker H, Krabbe P, Ruers T. Improved selection of patients for hepatic surgery of colorectal liver metastases with FDG-PET: A randomized study. J Clin Oncol (Meeting Abstracts) 2008;26:4004.
    1. Ychou M, Hohenberger W, Thezenas S, Navarro M, Gascon P, Bokemeyer C, Shacham-Shmueli E, Rivera F, Kwok-Keung Choi C, Santoro A. Randomized phase III trial comparing infused 5-fluorouracil/folinic acid (LV5FU) versus LV5FU+irinotecan (LV5FU+IRI) as adjuvant treatment after complete resection of liver metastases from colorectal cancer (LMCRC). (CPT-GMA-301) J Clin Oncol (Meeting Abstracts) 2008;26:LBA4013.
    1. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Wolmark N. Initial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer. J Clin Oncol (Meeting Abstracts) 2008;26:4006.
    1. Wolmark N, Wieand S, Kuebler PJ, Colangelo L, O'Connell MJ, Yothers G. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07. J Clin Oncol (Meeting Abstracts) 2008;26:LBA4005.
    1. Wolmark N, Wieand S, Kuebler JP, Colangelo L, Smith RE. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07. J Clin Oncol (Meeting Abstracts) 2005;23:LBA3500.
    1. de Gramont A, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Lorenzato C, Andre T. Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. J Clin Oncol (Meeting Abstracts) 2007;25:4007.
    1. Quasar Collaborative Group, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020–2029. doi: 10.1016/S0140-6736(07)61866-2.
    1. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–257. doi: 10.1056/NEJMoa022289.
    1. Sargent DJ, Marsoni S, Thibodeau SN, Labianca R, Hamilton SR, Torri V, Monges G, Ribic C, Grothey A, Gallinger S. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials. J Clin Oncol (Meeting Abstracts) 2008;26:4008.
    1. Benson AB., III New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal approaches in early-stage disease. Clin Cancer Res. 2007;13:6913s–6920s. doi: 10.1158/1078-0432.CCR-07-1188.
    1. Grothey A, Hart LL, Rowland KM, Ansari RH, Alberts SR, Chowhan NM, Shpilsky A, Hochster HS. Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial. J Clin Oncol (Meeting Abstracts) 2008;26:4010.
    1. Maindrault-Goebel F, Tournigand C, Andre T, Carola E, Mabro M, Artru P, Louvet C, de GA. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann Oncol. 2004;15:1210–1214. doi: 10.1093/annonc/mdh305.
    1. Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne P-L, Rivera F, Chirivella I, Perez-Staub N, Louvet C, Andre T, Tabah-Fisch I, de Gramont A. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer – a GERCOR study. J Clin Oncol. 2006;24:394–400. doi: 10.1200/JCO.2005.03.0106.
    1. Nikcevich DA, Grothey A, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, Wender DB, Novotny PJ, Windschitl HE, Loprinzi CL. Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: Results of the phase III placebo-controlled, double-blind NCCTG trial N04C7. J Clin Oncol (Meeting Abstracts) 2008;26:4009.
    1. Chu QD, Khushalani N, Javle MM, Douglass HO, Jr, Gibbs JF. Should adjuvant therapy remain the standard of care for patients with resected adenocarcinoma of the pancreas? Ann Surg Oncol. 2003;10:539–545. doi: 10.1245/ASO.2003.06.015.
    1. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Buchler MW. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358:1576–1585. doi: 10.1016/S0140-6736(01)06651-X.
    1. Berger AC, Garcia M, Jr, Hoffman JP, Regine WF, Abrams RA, Safran H, Konski A, Benson AB, III, MacDonald J, Willett CG. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol. 2008;26:5918–5922. doi: 10.1200/JCO.2008.18.6288.
    1. Regine WF, Winter KW, Abrams R, Safran H, Hoffman JP, Konski A, Benson AB, MacDonald JS, Willett CG, Rich TA. RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. J Clin Oncol (Meeting Abstracts) 2006;24:4007.
    1. Neuhaus P, Riess H, Post S, Gellert K, Ridwelski K, Schramm H, Zuelke C, Fahlke J, Langrehr J, Burkart C, Oettle H. CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC) J Clin Oncol (Meeting Abstracts) 2008;26:LBA4504.
    1. Picozzi VJ, Abrams RA, Traverso LW, O'Reilly EM, Greeno E, Martin RC, Wilfong LS, Decker PA, Pisters PW, Posner MC. ACOSOG Z05031: Report on a multicenter, phase II trial for adjuvant therapy of resected pancreatic cancer using cisplatin, 5- FU, and alpha-interferon. J Clin Oncol (Meeting Abstracts) 2008;26:4505.
    1. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–1966. doi: 10.1200/JCO.2006.07.9525.
    1. Vervenne W, Bennouna J, Humblet Y, Gill S, Moore MJ, Van Laethem J, Shang A, Cosaert J, Verslype C, Van Cutsem E. A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer. J Clin Oncol (Meeting Abstracts) 2008;26:4507.
    1. Kindler HL, Gangadhar T, Karrison T, Hochster HS, Moore MJ, Micetich K, Sun W, Catenacci DV, Stadler WM, Vokes EE. Final analysis of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC) J Clin Oncol (Meeting Abstracts) 2008;26:4502.
    1. Mitry E, Dahan L, Ychou M, Arthaud J, Gasmi M, Raoul J, Mariette C, Phelip JM, Bedenne L, Seitz J, Federation Francophone de Cancerologie D. LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD 0301) J Clin Oncol (Meeting Abstracts) 2008;26:4513.
    1. Pelzer U, Kubica K, Stieler J, Schwaner I, Heil G, Gorner M, Molle M, Hilbig A, Dorken B, Riess H, Oettle H. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol (Meeting Abstracts) 2008;26:4508.
    1. Drengler RL, Smith LS, Wood TE, Borad MJ, Ramanathan RK, Laheru DA, Hidalgo M, Von Hoff DD. Phase I study of nab-paclitaxel and gemcitabine combination in patients with advanced pancreatic cancer. J Clin Oncol (Meeting Abstracts) 2008;26:15523.
    1. O'Reilly EM, Niedzwiecki D, Hollis DR, Bekaii-Saab TS, Pluard T, Duffy A, Overcash F, Ivy SP, Goldberg RM. A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603. J Clin Oncol (Meeting Abstracts) 2008;26:4515.
    1. Iqbal S, Lenz HJ, Yang D, Ramanathan RK, Bahary N, Shibata S, Morgan RJ, Jr, Gandara DR. A randomized phase II study of BAY 43–9006 in combination with gemcitabine in metastatic pancreatic carcinoma: A California Cancer Consortium study (CCC-P) J Clin Oncol (Meeting Abstracts) 2008;26:11082.
    1. Wolpin BM, Hezel AF, Ryan DP, Abrams TA, Meyerhardt JA, Blaszkowsky LS, Clark JW, Allen B, Regan EM, Fuchs CS. Phase II study of RAD001 in previously treated patients with metastatic pancreatic cancer. J Clin Oncol (Meeting Abstracts) 2008;26:4614.
    1. Kim GP, Haddock M, Foster NR, Bollinger J, Stella PJ, Kugler JW, Alberts SR, Martenson J. Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU), and radiation therapy (RT) followed by gemcitabine (GEM) in patients with unresectable pancreatic cancer. J Clin Oncol (Meeting Abstracts) 2008;26:15553.
    1. Huguet F, Andre T, Hammel P, Artru P, Balosso J, Selle F, Deniaud-Alexandre E, Ruszniewski P, Touboul E, Labianca R, de Gramont A, Louvet C. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007;25:326–331. doi: 10.1200/JCO.2006.07.5663.
    1. Jimeno A, Solomon A, Karikari C, Garrido-Laguna I, Trusty D, Hruban R, Schulick R, Cameron J, Maitra A, Hidalgo M. A prospective validation of a direct tumor xenograft model in pancreatic ductal adenocarcinoma (PDA) J Clin Oncol (Meeting Abstracts) 2008;26:4500.
    1. Javle MM, Okazaki T, Evans DB, Wolff RA, Abbruzzese JL, Li D. Polymorphisms of genes involved in gemcitabine metabolism correlate with prognosis in patients receiving neoadjuvant therapy for pancreatic cancer. J Clin Oncol (Meeting Abstracts) 2008;26:4501.
    1. Collisson EA, Das D, Mori R, Hoffmann AC, Kim GE, Hajnal R, Danenberg PV, Cooc J, Danenberg KD, Tempero MA. Use of whole genome expression analysis of pancreatic adenocarcinoma to predict prognosis after OXi4503 surgery. J Clin Oncol (Meeting Abstracts) 2008;26:4503.
    1. Igaki H, Kato H, Ando N, Shinoda M, Shimizu H, Nakamura T, Ozawa S, Yabusaki H, Aoyama N, Kurita A, Fukuda H. A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907) J Clin Oncol (Meeting Abstracts) 2008;26:4510.
    1. Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, Takiyama W, Watanabe H, Isono K, Aoyama N, Makuuchi H, Tanaka O, Yamana H, Ikeuchi S, Kabuto T, Nagai K, Shimada Y, Kinjo Y, Fukuda H. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study – JCOG9204. J Clin Oncol. 2003;21:4592–4596. doi: 10.1200/JCO.2003.12.095.
    1. Kleinberg L, Powell ME, Forastiere AA, Keller S, Anne P, Benson AB. Survival outcome of E1201: An Eastern Cooperative Oncology Group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/radiotherapy (RT) or irinotecan/cisplatin/RT in endoscopy with ultrasound (EUS) staged esophageal adenocarcinoma. J Clin Oncol (Meeting Abstracts) 2008;26:4532.
    1. Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310–2317. doi: 10.1200/JCO.2005.00.034.
    1. Stahl M, Wilke H, Lehmann N, Stuschke M, German Oesophageal Cancer Study Group Long-term results of a phase III study investigating chemoradiation with and without surgery in locally advanced squamous cell carcinoma (LA-SCC) of the esophagus. J Clin Oncol (Meeting Abstracts) 2008;26:4530.
    1. Kang Y, Chang H, Zang D, Lee J, Kim T, Yang D, Jang S, Yook J, Oh S, Kim B. Postoperative adjuvant chemotherapy for grossly serosa-positive advanced gastric cancer: A randomized phase III trial of intraperitoneal cisplatin and early mitomycin-C plus long-term doxifluridine plus cisplatin (iceMFP) versus mitomycin-C plus short- term doxifluridine (Mf) (AMC 0101) (NCT00296322) J Clin Oncol (Meeting Abstracts) 2008;26:LBA4511.
    1. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Marabotti C, Van Cutsem E. Clinical Benefit With Docetaxel Plus Fluorouracil and Cisplatin Compared With Cisplatin and Fluorouracil in a Phase III Trial of Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study Group. J Clin Oncol. 2007;25:3205–3209. doi: 10.1200/JCO.2006.10.4968.
    1. Ridwelski K, Fahlke J, Kettner E, Schmidt C, Keilholz U, Quietzsch D, Assmann M, Stauch M, Zierau K, Lippert H. Docetaxel-cisplatin (DC) versus 5-fluorouracil-leucovorin-cisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary results of a phase III study. J Clin Oncol (Meeting Abstracts) 2008;26:4512.
    1. Gold PJ, Goldman B, Iqbal S, Leichman LP, Lenz HJ, Blanke CD. Cetuximab as second-line therapy in patients with metastatic esophageal cancer: A phase II Southwest Oncology Group Study. J Clin Oncol (Meeting Abstracts) 2008;26:4536.
    1. Lordick F, Lorenzen S, Al-Batran S, Hofheinz R, Thuss-Patience PC, Porschen R, Rothling N, Schuster T, Peschel C, Arbeitsgemeinschaft Internistische O. Cetuximab and cisplatin/5-FU (CF) versus CF in first-line metastatic squamous cell carcinoma of the esophagus (MESCC): A randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) J Clin Oncol (Meeting Abstracts) 2008;26:4546.
    1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, de Oliveira AC, Santoro A, Raoul J-L, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz J-F, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, the SISG. Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med. 2008;359:378–390. doi: 10.1056/NEJMoa0708857.
    1. Raoul J, Santoro A, Beaugrand M, Marrero JA, Moscovici M, Shan M, Nadel A, Voliotis D, Bruix J, Llovet JM. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to ECOG performance status: A subanalysis from the SHARP trial. J Clin Oncol (Meeting Abstracts) 2008;26:4587.
    1. Cheng A, Kang Y, Chen Z, Tsao C, Qin S, Kim J, Burock K, Zou J, Voliotis D, Guan ZZ. Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. J Clin Oncol (Meeting Abstracts) 2008;26:4509.
    1. Abou-Alfa GK, Amadori D, Santoro A, Figer A, De Greve J, Lathia C, Voliotis D, Anderson S, Moscovici M, Ricci S. Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis? J Clin Oncol (Meeting Abstracts) 2008;26:4518.
    1. Zhu AX, Sahani DV, di Tomaso E, Duda DG, Catalano OA, Ancukiewicz M, Blaszkowsky LS, Abrams TA, Ryan DP, Jain RK. Sunitinib monotherapy in patients with advanced hepatocellular carcinoma (HCC): Insights from a multidisciplinary phase II study. J Clin Oncol (Meeting Abstracts) 2008;26:4521.
    1. Holen KD, Mahoney MR, LoConte NK, Szydlo DW, Picus J, Maples WJ, Kim GP, Pitot HC, Philip PA, Thomas JP, Erlichman CE. Efficacy report of a multicenter phase II trial testing a biologic-only combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer (BC): A Phase II Consortium (P2C) study. J Clin Oncol (Meeting Abstracts) 2008;26:4522.
    1. Gruenberger B, Schueller J, Kaczirek K, Bergmann M, Klose W, Bischof M, Schernthaner G, Gruenberger T. Efficacy results of cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with advanced or metastatic cholangiocarcinoma: A single centre phase II study. J Clin Oncol (Meeting Abstracts) 2008;26:4586.
    1. Dealis C, Bertolini F, Malavasi N, Zironi S, Boni C, Banzi M, Aitini E, Cavazzini G, Luppi G, Conte PF. A phase II trial of sorafenib (SOR) in patients (pts) with advanced cholangiocarcinoma (CC) J Clin Oncol (Meeting Abstracts) 2008;26:4590.
    1. Overman MJ, Varadhachary GR, Lin E, Morris J, Adinin R, Abbruzzese JL, Wolff RA. Final response data of a phase II study of capecitabine and oxaliplatin (CAPOX) in advanced adenocarcinoma of the small bowel or ampulla of Vater. J Clin Oncol (Meeting Abstracts) 2008;26:4538.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir